BACKGROUND: Ventilatory efficiency (VE/VCO(2) slope) and peak oxygen consumption (VO) provide robust prognostic information in patients with heart failure undergoing cardiopulmonary exercise testing (CPX). The purpose of this study is to assess the change in prognostic characteristics of CPX at different time intervals. METHODS AND RESULTS: Seven hundred ninety-one subjects (74% male, mean age: 60.7+/-12.9 years, ejection fraction: 34.6+/-15.0%, ischemic etiology: 51%) underwent CPX and were tracked for major cardiac events over a 4-year period. All event-free subjects were tracked for at least 3 years. Mean VE/VCO(2) slope and peak VO(2) were 35.0+/-10.0 and 16.0+/-6.4 mL O(2) . kg(-1) . min(-1), respectively. There were a total of 263 major cardiac events (199 deaths, 45 transplants, and 19 left ventricular assist device implantations). Both continuous and dichotomous expressions of the VE/VCO(2) slope and peak VO(2) were prognostically significant up to 18 months post-CPX. Continuous and dichotomous expressions of the VE/VCO(2) slope remained prognostically significant up to 36 months post-CPX, whereas peak VO(2) was not predictive during the third and fourth year of follow-up. In a multivariate analysis, the VE/VCO(2) slope was consistently the superior prognostic marker, whereas peak VO(2) added predictive value and was retained in the regression up to 18 months post-CPX. CONCLUSIONS: These results indicate that commonly assessed CPX variables retain prognostic value for at least 2 years. The VE/VCO(2) slope is the superior predictor of adverse events throughout follow-up, although peak VO(2) provides additive prognostic information during the first 2 years of follow-up.
BACKGROUND: Ventilatory efficiency (VE/VCO(2) slope) and peak oxygen consumption (VO) provide robust prognostic information in patients with heart failure undergoing cardiopulmonary exercise testing (CPX). The purpose of this study is to assess the change in prognostic characteristics of CPX at different time intervals. METHODS AND RESULTS: Seven hundred ninety-one subjects (74% male, mean age: 60.7+/-12.9 years, ejection fraction: 34.6+/-15.0%, ischemic etiology: 51%) underwent CPX and were tracked for major cardiac events over a 4-year period. All event-free subjects were tracked for at least 3 years. Mean VE/VCO(2) slope and peak VO(2) were 35.0+/-10.0 and 16.0+/-6.4 mL O(2) . kg(-1) . min(-1), respectively. There were a total of 263 major cardiac events (199 deaths, 45 transplants, and 19 left ventricular assist device implantations). Both continuous and dichotomous expressions of the VE/VCO(2) slope and peak VO(2) were prognostically significant up to 18 months post-CPX. Continuous and dichotomous expressions of the VE/VCO(2) slope remained prognostically significant up to 36 months post-CPX, whereas peak VO(2) was not predictive during the third and fourth year of follow-up. In a multivariate analysis, the VE/VCO(2) slope was consistently the superior prognostic marker, whereas peak VO(2) added predictive value and was retained in the regression up to 18 months post-CPX. CONCLUSIONS: These results indicate that commonly assessed CPX variables retain prognostic value for at least 2 years. The VE/VCO(2) slope is the superior predictor of adverse events throughout follow-up, although peak VO(2) provides additive prognostic information during the first 2 years of follow-up.
Authors: Raymond J Gibbons; Gary J Balady; J Timothy Bricker; Bernard R Chaitman; Gerald F Fletcher; Victor F Froelicher; Daniel B Mark; Ben D McCallister; Aryan N Mooss; Michael G O'Reilly; William L Winters; Raymond J Gibbons; Elliott M Antman; Joseph S Alpert; David P Faxon; Valentin Fuster; Gabriel Gregoratos; Loren F Hiratzka; Alice K Jacobs; Richard O Russell; Sidney C Smith Journal: J Am Coll Cardiol Date: 2002-10-16 Impact factor: 24.094
Authors: V G Florea; M Y Henein; S D Anker; D P Francis; J S Chambers; P Ponikowski; A J Coats Journal: Eur Heart J Date: 2000-01 Impact factor: 29.983
Authors: Martha J Radford; J Malcolm O Arnold; Susan J Bennett; Michael P Cinquegrani; John G F Cleland; Edward P Havranek; Paul A Heidenreich; John D Rutherford; John A Spertus; Lynne Warner Stevenson; David C Goff; Frederick L Grover; David J Malenka; Eric D Peterson; Rita F Redberg Journal: Circulation Date: 2005-09-14 Impact factor: 29.690
Authors: Ross Arena; Jonathan Myers; Syed Salman Aslam; Elsa B Varughese; Mary Ann Peberdy Journal: Int J Cardiol Date: 2005-07-19 Impact factor: 4.164
Authors: Wayne C Levy; Dariush Mozaffarian; David T Linker; Santosh C Sutradhar; Stefan D Anker; Anne B Cropp; Inder Anand; Aldo Maggioni; Paul Burton; Mark D Sullivan; Bertram Pitt; Philip A Poole-Wilson; Douglas L Mann; Milton Packer Journal: Circulation Date: 2006-03-13 Impact factor: 29.690
Authors: Todd Dardas; Yanhong Li; Shelby D Reed; Christopher M O'Connor; David J Whellan; Stephen J Ellis; Kevin A Schulman; William E Kraus; Daniel E Forman; Wayne C Levy Journal: J Heart Lung Transplant Date: 2015-03-26 Impact factor: 10.247
Authors: Brian J Andonian; Nicolas Hardy; Alon Bendelac; Nicholas Polys; William E Kraus Journal: Curr Sports Med Rep Date: 2021-10-01 Impact factor: 2.669
Authors: Paul J Chase; Aarti Kenjale; Lawrence P Cahalin; Ross Arena; Paul G Davis; Jonathan Myers; Marco Guazzi; Daniel E Forman; Euan Ashley; Mary Ann Peberdy; Erin West; Christopher T Kelly; Daniel R Bensimhon Journal: JACC Heart Fail Date: 2013-09-11 Impact factor: 12.035
Authors: Marco Guazzi; Volker Adams; Viviane Conraads; Martin Halle; Alessandro Mezzani; Luc Vanhees; Ross Arena; Gerald F Fletcher; Daniel E Forman; Dalane W Kitzman; Carl J Lavie; Jonathan Myers Journal: Circulation Date: 2012-09-05 Impact factor: 29.690
Authors: Joachim Proff; Béla Merkely; Roland Papp; Corinna Lenz; Peter Nordbeck; Christian Butter; Juergen Meyerhoefer; Michael Doering; Dean J MacCarter; Katharina Ingel; Thomas Thouet; Ulf Landmesser; Mattias J Roser Journal: Europace Date: 2021-11-08 Impact factor: 5.214